+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 205 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a study drug called LY4065967 for treating chronic low back pain CLBP. This trial is part of a larger master protocol aimed at speeding up the development of new treatments for chronic pain conditions. The study focuses on adults with a history of low back pain lasting at least three months. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study uses a double-blind design, meaning neither the participants nor the researchers know who receives the study drug or placebo. The treatment phase lasts for 8 weeks, during which participants take the assigned medication regularly. During the study, participants will be assessed at the start and at week 8 for changes in pain intensity using a numeric rating scale. Other evaluations include overall improvement, worst pain intensity, sleep quality, emotional functioning, use of rescue medication, and disability related to back pain. The trial includes safety monitoring and will continue until April 2027, with visits scheduled to track these outcomes.

Age: 18Years +All GendersPhase 2
36 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating diabetic peripheral neuropathic pain DPNP. This study is part of a larger chronic pain master protocol aimed at speeding up the development of new treatments for chronic pain conditions. Participants have diabetes and suffer from symmetrical nerve pain in their lower limbs. Participants will be randomly assigned to receive either LY4065967 or a placebo, both given orally. The study is double-blinded, meaning neither participants nor researchers know who receives which treatment. The treatment phase will last 8 weeks, during which pain and related symptoms will be monitored and compared between the groups. During the study, participants will have their pain intensity measured using a numeric rating scale at the start and at week 8. Other assessments include pain interference, overall improvement, sleep quality, emotional functioning, and daily use of rescue medication. The study involves regular monitoring to evaluate these outcomes and ensure participant safety throughout the 8-week treatment period.

Age: 18Years +All GendersPhase 2
36 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug LY4065967 for treating knee pain caused by osteoarthritis. This study is part of a larger effort called the chronic pain master protocol to speed up the development of new treatments for chronic pain conditions. The trial is a randomized, placebo-controlled Phase 2 study focusing on adults with knee osteoarthritis pain lasting more than 12 weeks. Participants will be randomly assigned to receive either LY4065967 or a placebo, both administered orally. The study compares these two groups to assess how well LY4065967 works in reducing knee pain and improving related symptoms. Treatment effects will be measured over an 8-week period, with evaluations at the start and end of this timeframe. During the study, participants will undergo regular assessments including pain intensity ratings using the Numeric Rating Scale, evaluations of arthritis symptoms, sleep quality, emotional functioning, and use of any rescue medication. Researchers will monitor the safety and effectiveness of the treatment through these measures. The total study duration for participants is approximately 8 weeks, with monitoring at baseline and week 8 to observe changes from the start of treatment.

Age: 40Years +All GendersPhase 2
36 locations
E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations
L

Actively Recruiting

Researchers are conducting the TEMPUS AQUARIUS Study, an observational, long-term research focused on patients with blood cancers such as Acute Myeloid Leukemia AML and Follicular Lymphoma FL. The study aims to discover molecular biomarkers by collecting detailed molecular and clinical data to better understand how these markers relate to real-world patient outcomes. This study is sponsored by Tempus AI and follows patients over several years. Participants are grouped into cohorts based on their diagnosis and disease status, including newly diagnosed AML patients and various subgroups of FL patients distinguished by disease stage and risk. The study involves collecting samples like blood, leftover tissue, and bone marrow during patients regular medical care without any additional interventions. This approach allows researchers to observe and analyze disease progression and treatment effects through routine clinical monitoring. Participants will be involved over a period of up to five years, during which molecular and clinical data are gathered from biospecimens and medical records. The primary measurement is the assessment of biomarker patterns in disease progression and baseline samples, correlated with clinical outcomes. There are no study treatments to receive, and participation involves providing consent and biospecimens during their regular care visits.

Age: 0Years +All Genders
13 locations
T

Actively Recruiting

Researchers are conducting a prospective, longitudinal, non-interventional multicenter study involving participants with head and neck squamous cell carcinoma HNSCC. The study focuses on patients with metastatic or unresectable recurrent HNSCC who are planned to receive first-line immunotherapy or combination therapy. This study aims to explore molecular biomarkers from tissue and blood samples to better understand prognostic and predictive markers, and to guide future biomarker research. Participants will not receive any experimental treatment as this is an observational study. Instead, molecular profiling will be done using tumor tissue and blood samples collected during their standard of care. The study plans to include up to 500 participants with tumors located in the pharynx, larynx, oral cavity, or oropharynx. There is no intervention, and participants will continue their planned first-line anti-PD1 or PDL1 therapy or combination treatment. Throughout the five-year study period, researchers will collect longitudinal blood samples and diagnostic or progression biopsy samples to examine changes in DNA, RNA, immune markers, and circulating tumor DNA ctDNA. These assessments aim to understand real-world outcomes, resistance mechanisms, and evaluate ctDNA as a response biomarker. Participants will provide informed consent, and their compliance with study procedures, including blood sample collection, will be monitored.

Age: 18Years +All Genders
32 locations
M

Actively Recruiting

Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.

Age: 18Years +All GendersPhase 2
64 locations
E

Actively Recruiting

This research aims to compare eye dryness after laser-assisted in situ keratomileusis LASIK surgery with eye dryness before receiving perioperative Miebo treatment in adults who have dry eye disease DED. The study evaluates the effect of using Miebo eye drops around the time of LASIK surgery to better understand its impact on dry eye symptoms. The study is sponsored by Vance Thompson Vision and is a phase 4, open-label interventional trial. Participants will use Miebo eye drops four times daily for one month before undergoing routine, uncomplicated bilateral LASIK surgery and continue using the drops for 1.5 months after the surgery. The treatment involves dosing each eye with Miebo eye drops and observing any changes in eye dryness symptoms over this period. During the study, participants will have their eye dryness measured using a visual analog scale VAS to compare symptoms before and after LASIK surgery while on Miebo treatment. The total study duration includes the month of treatment before surgery and 1.5 months after, with the primary outcome measured at 4 months. Participants will also undergo regular assessments and follow instructions to ensure the treatment and measurements are accurately recorded throughout the study.

Age: 18Years +All GendersPhase 4
4 locations
E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations

1-10 of 205

1